比较替格瑞洛和氯吡格雷在伴有高抗血小板反应的患者的使用，前者血小板功能恢复早.pdfVIP

Journal of Thrombosis and Haemostasis, 9: 1730–1737 DOI: 10.1111/j.1538-7836.2011.04419.x ORIGINAL ARTICLE Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses R . F . S T O R E Y , * K . P . B L I D E N , R . E C O B , * A . K A R U N A K A R A N , * K . B U T L E R , C . W E I , U . T A N T R Y and P. A. G U R B E L *NIHR Cardiovascular Biomedical Research Unit and Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; Sinai Center for Thrombosis Research, Baltimore, MD; and AstraZeneca, Wilmington, DE, USA To cite this article: Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, Tantry U, Gurbel PA. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 2011; 9: 1730–7. Keywords: antiplatelet therapy, clopidogrel, coronary artery Summary. Background: The rate of recovery of platelet disease, ticagrelor. function after discontinuation of P2Y12 inhibitors depends on the reversibility of the antiplatelet effect and the extent of the on- Introduction treatment response. P2Y12 inhibition increases the bleeding risk in patients requiring surgery. Objectives: To evaluate recovery The management of antiplatelet therapy in patients with of platelet function after discontinuation of ticagrelor vs. coronary artery disease (CAD), including those with acute clopidogrel in stable coronary artery disease (CAD) patients coronary syndromes (ACS), requires careful balancing of the with high levels of platelet inhibition (HPI) du